CRON:TSX-Cronos Group Inc (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 3.86

Change

-0.48 (-11.06)%

Market Cap

CAD 1.63B

Volume

0.25M

Avg Analyst Target

CAD 5.40 (+39.94%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Cronos Group Inc (CRON) Stock Analysis:
Based on the Cronos Group Inc stock forecasts from 9 analysts, the average analyst target price for Cronos Group Inc is CAD 5.40 over the next 12 months. Cronos Group Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Cronos Group Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Cronos Group Inc’s stock price was CAD 3.86. Cronos Group Inc’s stock price has changed by -15.54% over the past week, -0.52% over the past month and -56.77% over the last year.

About

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BHC:CA Bausch Health Companies Inc

-0.84 (-6.59%)

CAD4.61B N/A 13.60
APHA:CA Aphria Inc

N/A

CAD4.44B 57.08 598.01
TLRY:CA Tilray Inc

-0.60 (-9.93%)

CAD3.01B 49.11 N/A
WEED:CA Canopy Growth Corporation

-1.03 (-14.53%)

CAD2.83B N/A N/A
ACB:CA Aurora Cannabis Inc

-0.46 (-12.33%)

CAD0.85B 1,171.00 N/A
GUD:CA Knight Therapeutics Inc

+0.01 (+0.19%)

CAD0.61B 41.51 12.40
OGI:CA OrganiGram Holdings Inc

-0.10 (-6.49%)

CAD0.48B -99,999.99 N/A
HLS:CA HLS Therapeutics Inc

+0.09 (+0.67%)

CAD0.43B N/A 18.07
INCR-U:CA InterCure Ltd

N/A

CAD0.33B N/A 9.48
TH:CA Theratechnologies Inc

+0.21 (+7.17%)

CAD0.29B 954.70 80.88

ETFs Containing CRON:CA

Symbol Name Weight Mer Price(Change) Market Cap
HMMJ:CA Horizons Marijuana Life S.. 0.00 % 0.85 %

-0.28 (-6.48%)

CAD0.21B
SEED:CA Evolve Marijuana Fund 0.00 % 0.75 %

N/A

CAD3.63M
HMMJ-U:CA Horizons Marijuana Life S.. 0.00 % 0.85 %

-0.10 (-3.04%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.49% 68% D+ 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.49% 68% D+ 17% F
Trailing 12 Months  
Capital Gain -57.11% 60% D- 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.11% 60% D- 5% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.89% 67% D+ 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.89% 67% D+ 32% F
Risk Return Profile  
Volatility (Standard Deviation) 63.74% 27% F 13% F
Risk Adjusted Return 2.97% 67% D+ 21% F
Market Capitalization 1.63B 91% A- 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 46.76 43% F 11% F
Price/Book Ratio 0.97 44% F 71% C-
Price / Cash Flow Ratio -10.61 88% B+ 87% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -18.53% 66% D 15% F
Return on Invested Capital -36.75% 43% F 8% F
Return on Assets -7.03% 50% F 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 19.28 13% F 4% F
Short Percent 3.23% 21% F 45% F
Beta 1.51 52% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector